Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 55

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 55
---
 at Fair Value on a Recurring BasisEquity and Convertible Note InvestmentsThe Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands): Equity InvestmentsConvertible Notes ReceivableTotalBalance at December 31, 2022$15,877 $5,315 $21,192 Purchases— 6,758 6,758 Foreign currency adjustments— 61 61 Balance at December 31, 202315,877 12,134 28,011 Foreign currency adjustments— (236)(236)Balance at December 31, 2024$15,877 $11,898 $27,775 

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-29

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

During the year ended December 31, 2022, an impairment of an equity investment of $10.0 million was recorded in other, net in the consolidated statements of operations.Acquisition-Related Contingent ConsiderationThe Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $20.2 million and $24.7 million as of December 31, 2024 and 2023, respectively. Refer to Note 17, Contingent Consideration Gains, Restructuring Charges and Other, for more information.The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These inputs include, as applicable, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $